26 March 2024
26 March 2024
Hua Medicine will also evaluate the key secondary endpoints of pharmacokinetics and pharmacodynamics in the Phase I trial.
The US company is developing its BTX-A51 therapy as a treatment for acute myeloid leukaemia and solid tumours.
The trial will assess APG808's safety, tolerability and pharmacokinetics in healthy subjects.
The initial portion of the trial will help in analysing complete patient response, which is its primary endpoint.
The company will also use the funds to bolster its iNKT cell therapy pipeline.
The Trial Interactive eClinical platform is designed to simplify product development life cycles.
The DecisionDx-Melanoma test can identify the risk of an occurrence of metastasis, and sentinel lymph node positivity.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
